Evaluation of nevirapine-switch strategies for HIV treatment.
Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies. The weight of evidence demonstrates that a switch from a PI-based regimen to one containing nevirapine can be accomplished safely while maintaining virological suppression. There is no immunological cost. There is probably an overall benefit in terms of the metabolic milieu.
Cooper
C L
CL
Division of Infectious Diseases, University of Ottawa Hospital, The Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, Ontario, Canada. ccooper@ottawahospital.on.ca
D000328:Adult; D001315:Australia; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D005060:Europe; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine; D011788:Quality of Life; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000378:metabolism; D014481:United States
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine